Latest News and Press Releases

Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy.

Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025 – Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day...

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of...

New survey data show 94% of animal owners appreciate the work of veterinarians1, compared to only 49% of veterinary professionals feeling their profession is appreciated, among other findings.2The...

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of Managing Directors, to succeed Hubertus von...

        Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.       The...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with...

Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net salesCompany prepares new product launches starting in 2025Boehringer...

VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 avian influenza in just one shot.   H5 avian influenza...